FIGURE 3.

Therapeutic strategies for SYS. This figure summarizes some promising therapeutic advances with potential efficacy in addressing SYS, transcending symptomatic management. Notably, antisense oligonucleotides directed at truncated MAGEL2 could specifically address potential neomorphic effects. Abbreviations: AAV‐BDNF, adeno‐associated virus‐BDNF gene; ASO, antisense oligonucleotide; GH, growth hormone; Me, methylation signal; mRNA, messenger RNA; mut, mutation; OT, oxytocin; rhGH, recombinant human growth hormone; SYS, Schaaf–Yang syndrome; WT, wild type.